Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

LIPOSOME COMPANY ESTABLISHES PRINCETON LIPIDS division to supply purified phospholipids to the cosmetics industry. "Because of its affiliation with the Liposome Company, Princeton Lipids will be able to provide technical expertise in the field of liposomes to its customers," a Feb. 21 press release declares. The new unit is the outgrowth of two recent agreements. The first, signed in December with the Japanese firm Nichiyu Liposome Co., makes the Liposome Company the exclusive North American agent for Nichiyu Liposome Co.'s high purity phospholipid products. "Princeton Lipids will be one of the few U.S. companies capable of supplying commercial quantities of high purity lipids manufactured in a facility with a Drug Master File." The Liposome Company also serves as the North American sales agent for Nattermann Phospholipid GmbH under a more recent pact. "Princeton Lipids will be selling 'Naptides,'" described by the company as a liposome used in Europe as a raw material in cosmetic formulations. The U.S. market for liposome-formulated cosmetics is estimated at over $50 mil. in 1989. The development comes less than one week after the announcement of a proposed merger between the Liposome Company and Liposome Technology.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts